Skip to main content
Clinical Trials/NCT05882604
NCT05882604
Completed
Not Applicable

Treatment of Temporomandibular Joint Internal Derangement Using MESNA Injection

Tanta University1 site in 1 country60 target enrollmentStarted: March 1, 2023Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
60
Locations
1
Primary Endpoint
maximal interincisal opening (MIO)

Overview

Brief Summary

The pathogenesis of temporomandibular disorders focusing on the biochemistry of the synovial fluid in various stages of temporomandibular joint disease. The role of inflammation has been investigated and proposed as an underlying mechanism of pain and dysfunction of temporomandibular joint. MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the disulfide bonds between polypeptide chains of mucus. The tissue distribution of MESNA is negligible, and the elimination of the substance is rapidly and completely achieved by kidney

Detailed Description

Clarification (July 2025): Recruitment was completed in March 2023 following clinical scheduling and preliminary departmental clearance, while formal written ethical approval was finalized in early April 2023. All patients were followed up for one year, and the study was completed by March 2024.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patients with TMJ internal derangement with reduction

Exclusion Criteria

  • inflammatory or connective tissue disease
  • autoimmune disease history
  • neurologic problems

Arms & Interventions

Intra-articular injection with MESNA solution

Experimental

1 ml of MESNA will be injected intra-articular

Intervention: Mesna Injection (Drug)

Arthrocentesis with ringer solution

Active Comparator

ringer solution will be used for arthrocentesis

Intervention: Arthrocentesis with ringer solution (Drug)

Outcomes

Primary Outcomes

maximal interincisal opening (MIO)

Time Frame: 6 months

a digital caliper will be employed to measure the maximum interincisal opening pre and postoperative

Secondary Outcomes

  • Joint pain(6 months)
  • clicking sound(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Abdellatif Abdelfatah

Lecturer of oral and maxillofacial surgery

Tanta University

Study Sites (1)

Loading locations...

Similar Trials